Literature DB >> 6416861

L-norgestrel and progesterone have different influences on plasma lipoproteins.

L Fåhraeus, U Larsson-Cohn, L Wallentin.   

Abstract

Twenty-six postmenopausal women who had been on cutaneous oestradiol treatment for 3-6 months were given either 120 micrograms of 1-norgestrel (n = 13) or 300 mg of progesterone (n = 13) sequentially for another 6 months. The concentrations of cholesterol, phospholipids and triglycerides were determined in plasma and in the HDL, HDL2, HDL3, LDL and VLDL fractions before and after one, three and six cycles of progestin treatment. Already after 11 days on 1-norgestrel, the mean HDL cholesterol and the mean HDL phospholipid concentrations were reduced by 15%. The reduction of the HDL-lipids was mainly confined to the HDL2 fraction which was decreased by 25-30%. L-norgestrel also reduced the mean TG concentration both in the VLDL and the combined LDL + HDL fractions. Progesterone gave only minor changes of the plasma lipids and lipoproteins. Reduced HDL, especially HDL2, concentration, as induced by 1-norgestrel, might increase the risk for ischaemic heart disease. Therefore, it seems that, as regards the effects on the lipoproteins, progesterone might be more suitable than the 19-nortestosterone derivative 1-norgestrel for postmenopausal sequential hormonal therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6416861     DOI: 10.1111/j.1365-2362.1983.tb00127.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

Review 1.  Emerging Research on the Implications of Hormone Replacement Therapy on Coronary Heart Disease.

Authors:  Carson Keck; Marian Taylor
Journal:  Curr Atheroscler Rep       Date:  2018-10-22       Impact factor: 5.113

2.  Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits.

Authors:  J Haarbo; P Leth-Espensen; S Stender; C Christiansen
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

3.  Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease.

Authors:  C Nappi; P Affinito; C Di Carlo; G Esposito; U Montemagno
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

4.  Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats.

Authors:  Heba F Salem
Journal:  Int J Nanomedicine       Date:  2010-11-10

5.  The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model.

Authors:  Arunkumar Arumugam; Elaine A Lissner; Rajkumar Lakshmanaswamy
Journal:  Reprod Biol Endocrinol       Date:  2014-07-15       Impact factor: 5.211

Review 6.  Cardiovascular Risk/Benefit Profile of MHT.

Authors:  Paola Villa; Inbal Dona Amar; Maayan Shachor; Clelia Cipolla; Fabio Ingravalle; Giovanni Scambia
Journal:  Medicina (Kaunas)       Date:  2019-09-06       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.